Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases

NCT ID: NCT01954875

Last Updated: 2022-04-26

Basic Information

• Recruitment Status: WITHDRAWN
• Study Classification: OBSERVATIONAL
• Study Start Date: 2009-12-02
• Study Completion Date: 2019-07-02

Brief Summary

The etiology of many neurodegenerative diseases is unknown. A few studies have suggested the role of infection in the gastrointestinal tract in the etiology and pathogenesis of neurological diseases such as idiopathic Parkinson. For example, infection with Helicobacter pylori has been suggested to play a role in Parkinson disease. In addition, bacterial pathogens such as spirochetes and bacterial products such as cyanobacterial toxins have been speculated as the contributing factors in the development of amyotrophic lateral sclerosis (ALS). The effect of microbial composition of the gut in the pathogenesis of ALS is suspected. The difference in the bacterial profile of the gut has been documented in diseases such as inflammatory bowel disease and obesity.

The goal of this IRB protocol is to create a human tissue bank and to obtain patients' demographic information for future investigation of the role of bacterial pathogens and the role of gut flora composition in the development of neurodegenerative diseases including but not limited to ALS, Parkinson's disease, and multiple sclerosis.

Detailed Description

The purpose of this clinical trial is to create a bank of fecal and blood samples and associated coded demographic information for future investigation of the microbial etiology and pathophysiology of neurodegenerative diseases including but not limited to Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease and multiple sclerosis.

Approximately 300 adult participants (open to all races and both sexes) subjects will be recruited (i.e. 100 healthy controls, 100 subjects with other neurodegenerative diseases (not ALS) and 100 subjects with ALS).

Inclusion criteria permit all adults aged >18 years of age with the diagnosis of ALS who are willing to provide informed consent and patients who do not have a diagnosis of ALS and are willing to provide informed consent. Subjects who do not provide informed consent, have acute bacterial infection of the GI tract, and/or are being treated with antibiotics or probiotics within 28 days prior to sampling are excluded. A separate blood sample will not be taken from a subject if the maximum amount of samples allowed have been collected for standard care.

Upon arrival to the clinic, staff will provide the stool tissue bank protocol informed consent / HIPAA authorization document to eligible subjects for review. If subjects indicate a willingness to participate, the research coordinator or one of the participating investigators will review the informed consent form / HIPAA authorization with the subjects and answer any questions. If subjects agree to participate, they will sign the informed consent form / HIPAA authorization. Copies of the document will be made for subjects; originals will be filed in a locked cabinet.

Biological materials will be collected from the patient using either one or both of the following methods: as biological samples obtained specifically for the study (e.g. stool samples from all participating patients) or as extra material obtained specifically for research in addition to material collected as part of routine care (e.g., blood samples).

Subjects will be asked to consider participating in the stool tissue bank protocol. If subjects consent to donate extra samples for the bank, the samples will be obtained by the physicians or the clinic staff.

Two 10 ml venous blood samples for the ALS tissue bank will be collected 1) in a serum separator, and 2) in a tube containing the anticoagulant, EDTA (lavender top). Stool samples will be collected in sterile plastic cups. The blood and stool samples will be put on ice or refrigerated as promptly as possible until delivered to the ALS Research Laboratory at Cannon Research Center.

Samples will be de-identified by labeling with a research code prior to entering the laboratory. All information pertaining to the sample including a copy of the consent form and the master list of the research coding will be secured in a locked file cabinet. Personal health information (PHI) obtained will be entered into a separate security-protected database utilizing encryption technology and accessible only to authorized personnel. The samples, once coded, will be given to the appropriate laboratory technician for processing and analysis.

Blood samples will be centrifuged, the plasma and serum samples will be aliquoted in 1 ml tubes and stored at -80 C. The blood cells, separated from plasma, will be processed for DNA isolation immediately or stored at -80 C for later DNA extraction. Four ~25 mg aliquots of stool samples will be stored in sterile tubes at -80 C for future analysis. Storage freezers are locked, connected to emergency power and monitored by an alarm system that notifies laboratory personnel of malfunctions, etc.

In addition, a data collection form will be completed by the research staff to collect demographic, medical history, etc. as shown in Appendix C. The form will be linked to the tissue samples by an individual research code. This information is necessary for defining the tissue samples collected.

No formal sample size determination will be performed for this tissue bank protocol.

Conditions

Neurodegenerative Diseases; Amyotrophic Lateral Sclerosis; Multiple Sclerosis; Parkinson Disease

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

Subjects with ALS

subjects diagnosed with amyotrophic lateral sclerosis

No interventions assigned to this group

subjects with non-ALS neurodegenerative disease

subjects diagnosed with non-ALS neurodegenerative disease

No interventions assigned to this group

healthy controls

healthy subjects as controls

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• aged 18 years and older
• patients diagnosed with amyotrophic lateral sclerosis or other neurodegenerative disease, and healthy controls

Exclusion Criteria

• Subjects with acute bacterial infection of the GI tract
• Subjects on treatments with antibiotics or probiotics within 28 days prior to sampling

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Wake Forest University Health Sciences

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Benjamin R Brooks, MD

Role: PRINCIPAL_INVESTIGATOR

Director, Neuromuscular ALS/MDA Center and Neuromuscular/ALS Research Laboratory

Locations

Carolinas Medical Center - Dept of Neurology

Charlotte, North Carolina, United States

Countries

United States

Other Identifiers

CHS-Neurology-ALS stool sample

Identifier Type: -

Identifier Source: org_study_id